NCT02494258 2026-04-02
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
Celgene
Phase 2 Completed
Clinical Trials
30 trialsNCT06456463 2026-03-09
TRILLIUM
Stemline Therapeutics, Inc.
Phase 2 Recruiting
NCT05197426 2026-02-11
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission
Bristol-Myers Squibb
Phase 2 Active not recruiting
NCT04150029 2026-01-13
STIMULUS-AML1
Novartis
Phase 2 Terminated
NCT05201066 2026-01-07
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Novartis
Phase 2 Active not recruiting
NCT05413018 2025-12-08
An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
Bristol-Myers Squibb
Phase 2 Active not recruiting
NCT04266795 2025-10-21
PEVENAZA
Takeda
Phase 2 Completed
NCT06384261 2025-09-10
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
OncoVerity, Inc.
Phase 2 Recruiting
NCT04023526 2025-08-20
CULMINATE
OncoVerity, Inc.
Phase 2 Active not recruiting
NCT02546986 2025-08-08
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
Celgene
Phase 2 Completed
NCT04778410 2025-03-20
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
Gilead Sciences
Phase 2 Terminated
NCT03931291 2025-03-17
APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
Aprea Therapeutics
Phase 2 Completed
NCT06858618 2025-03-05
FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 2 Active not recruiting
NCT04905407 2025-02-24
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Syros Pharmaceuticals
Phase 2 Terminated
NCT02807558 2024-12-13
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Syros Pharmaceuticals
Phase 2 Completed
NCT02250326 2024-09-19
abound2L+
Celgene
Phase 2 Completed
NCT06532058 2024-08-01
Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia
Changzhou Qianhong Bio-pharma Co., Ltd.
Phase 2 Recruiting
NCT02775903 2023-02-28
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
Celgene
Phase 2 Completed
NCT02610777 2022-09-19
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
Takeda
Phase 2 Completed
NCT04264806 2022-05-20
A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)
Janssen Research & Development, LLC
Phase 2 Withdrawn
NCT01912274 2021-02-09
Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Helsinn Healthcare SA
Phase 2 Completed
NCT02450877 2019-12-20
A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.
Celgene
Phase 2 Completed
NCT02447666 2019-07-11
Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)
Celgene
Phase 2 Completed
NCT01358734 2019-06-25
A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia
Celgene
Phase 2 Completed
NCT02374099 2018-12-14
Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
Celgene
Phase 2 Terminated
NCT02269943 2018-12-12
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
Celgene
Phase 2 Completed
NCT00384839 2018-10-25
Vidaza to Restore Hormone Thx Prostate
US Oncology Research
Phase 2 Completed
NCT02147873 2016-10-20
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
TetraLogic Pharmaceuticals
Phase 2 Terminated
NCT00543582 2015-07-01
MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma
Mirati Therapeutics Inc.
Phase 2 Terminated
NCT00666497 2015-05-08
Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Mirati Therapeutics Inc.
Phase 2 Terminated